The phase III EXCLAIM-2 cohort (NCT04129502) will directly compare first-line platinum-based chemotherapy versus mobocertinib in treatment-naïve EGFR exon 20 insertion NSCLC patients, with median PFS as a primary endpoint [57]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.